Acetazolamide Per os for Decompensation of Heart Failure
Recruiting
Phase 4
Interventional Study
Chronic Heart Failure
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 400 (estimated)
- Sponsor
- Samara State Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF), while its prevalence is progressively increasing annually.
Acute decompensation of CHF is understood as a rapid increas…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Men or women aged 18 years and older
* Decompensated CHF NYHA II-IV, which required intravenous administration of diuretics
* Any injection fraction of left ventricle\*
* Signed informed consent to participate in the study.
* in patients with LV LV ≥ 50%: the presence of st…
Contacts